vs
ADMA BIOLOGICS, INC.（ADMA）与GRID DYNAMICS HOLDINGS, INC.（GDYN）财务数据对比。点击上方公司名可切换其他公司
ADMA BIOLOGICS, INC.的季度营收约是GRID DYNAMICS HOLDINGS, INC.的1.3倍（$139.2M vs $104.1M），ADMA BIOLOGICS, INC.净利率更高（35.5% vs -1.4%，领先36.9%），ADMA BIOLOGICS, INC.同比增速更快（18.4% vs 3.7%），过去两年ADMA BIOLOGICS, INC.的营收复合增速更高（30.4% vs 12.0%）
ADMA生物制剂公司是一家专注于研发、生产及商业化特种血浆来源免疫球蛋白疗法的生物制药企业，主要面向美国市场，为原发性免疫缺陷及其他免疫相关疾病患者、医护人员和医疗机构提供免疫健康领域的治疗方案。
Escape Dynamics Inc.是一家总部位于科罗拉多州的科技企业，活跃于2010年至2015年，核心业务方向是研发可单级入轨、依靠电磁驱动的可重复使用航天飞机，并推动该项目实现商业化落地。
ADMA vs GDYN — 直观对比
营收规模更大
ADMA
是对方的1.3倍
$104.1M
营收增速更快
ADMA
高出14.7%
3.7%
净利率更高
ADMA
高出36.9%
-1.4%
两年增速更快
ADMA
近两年复合增速
12.0%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $139.2M | $104.1M |
| 净利润 | $49.4M | $-1.5M |
| 毛利率 | 63.8% | 34.8% |
| 营业利润率 | 45.1% | 61.7% |
| 净利率 | 35.5% | -1.4% |
| 营收同比 | 18.4% | 3.7% |
| 净利润同比 | -55.9% | -150.6% |
| 每股收益（稀释后） | $0.20 | $-0.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADMAGDYN
| Q1 26 | — | $104.1M | ||
| Q4 25 | $139.2M | $106.2M | ||
| Q3 25 | $134.2M | $104.2M | ||
| Q2 25 | $122.0M | $101.1M | ||
| Q1 25 | $114.8M | $100.4M | ||
| Q4 24 | $117.5M | $100.3M | ||
| Q3 24 | $119.8M | $87.4M | ||
| Q2 24 | $107.2M | $83.0M |
净利润ADMAGDYN
| Q1 26 | — | $-1.5M | ||
| Q4 25 | $49.4M | $306.0K | ||
| Q3 25 | $36.4M | $1.2M | ||
| Q2 25 | $34.2M | $5.3M | ||
| Q1 25 | $26.9M | $2.9M | ||
| Q4 24 | $111.9M | $4.5M | ||
| Q3 24 | $35.9M | $4.3M | ||
| Q2 24 | $32.1M | $-817.0K |
毛利率ADMAGDYN
| Q1 26 | — | 34.8% | ||
| Q4 25 | 63.8% | 34.0% | ||
| Q3 25 | 56.3% | 33.3% | ||
| Q2 25 | 55.1% | 34.1% | ||
| Q1 25 | 53.2% | 36.8% | ||
| Q4 24 | 53.9% | 36.9% | ||
| Q3 24 | 49.8% | 37.4% | ||
| Q2 24 | 53.6% | 35.6% |
营业利润率ADMAGDYN
| Q1 26 | — | 61.7% | ||
| Q4 25 | 45.1% | 0.5% | ||
| Q3 25 | 38.0% | -0.2% | ||
| Q2 25 | 35.1% | -0.1% | ||
| Q1 25 | 30.4% | -2.0% | ||
| Q4 24 | 32.6% | 1.3% | ||
| Q3 24 | 33.1% | 2.4% | ||
| Q2 24 | 36.6% | 0.0% |
净利率ADMAGDYN
| Q1 26 | — | -1.4% | ||
| Q4 25 | 35.5% | 0.3% | ||
| Q3 25 | 27.1% | 1.1% | ||
| Q2 25 | 28.1% | 5.2% | ||
| Q1 25 | 23.4% | 2.9% | ||
| Q4 24 | 95.2% | 4.5% | ||
| Q3 24 | 30.0% | 4.9% | ||
| Q2 24 | 29.9% | -1.0% |
每股收益（稀释后）ADMAGDYN
| Q1 26 | — | $-0.02 | ||
| Q4 25 | $0.20 | $0.01 | ||
| Q3 25 | $0.15 | $0.01 | ||
| Q2 25 | $0.14 | $0.06 | ||
| Q1 25 | $0.11 | $0.03 | ||
| Q4 24 | $0.45 | $0.06 | ||
| Q3 24 | $0.15 | $0.05 | ||
| Q2 24 | $0.13 | $-0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $87.6M | $327.5M |
| 总债务越低越好 | $72.1M | — |
| 股东权益账面价值 | $477.3M | $530.1M |
| 总资产 | $624.2M | $605.0M |
| 负债/权益比越低杠杆越低 | 0.15× | — |
8季度趋势，按日历期对齐
现金及短期投资ADMAGDYN
| Q1 26 | — | $327.5M | ||
| Q4 25 | $87.6M | $342.1M | ||
| Q3 25 | $61.4M | $338.6M | ||
| Q2 25 | $90.3M | $336.8M | ||
| Q1 25 | $71.6M | $325.5M | ||
| Q4 24 | $103.1M | $334.7M | ||
| Q3 24 | $86.7M | $231.3M | ||
| Q2 24 | $88.2M | $256.0M |
总债务ADMAGDYN
| Q1 26 | — | — | ||
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益ADMAGDYN
| Q1 26 | — | $530.1M | ||
| Q4 25 | $477.3M | $542.1M | ||
| Q3 25 | $431.2M | $537.7M | ||
| Q2 25 | $398.3M | $532.2M | ||
| Q1 25 | $373.4M | $517.4M | ||
| Q4 24 | $349.0M | $517.8M | ||
| Q3 24 | $231.9M | $400.2M | ||
| Q2 24 | $188.3M | $388.4M |
总资产ADMAGDYN
| Q1 26 | — | $605.0M | ||
| Q4 25 | $624.2M | $612.9M | ||
| Q3 25 | $568.7M | $613.2M | ||
| Q2 25 | $558.4M | $608.9M | ||
| Q1 25 | $510.6M | $590.9M | ||
| Q4 24 | $488.7M | $592.2M | ||
| Q3 24 | $390.6M | $477.3M | ||
| Q2 24 | $376.4M | $443.6M |
负债/权益比ADMAGDYN
| Q1 26 | — | — | ||
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $35.6M | — |
| 自由现金流经营现金流 - 资本支出 | $34.6M | — |
| 自由现金流率自由现金流/营收 | 24.8% | — |
| 资本支出强度资本支出/营收 | 0.8% | — |
| 现金转化率经营现金流/净利润 | 0.72× | — |
| 过去12个月自由现金流最近4个季度 | $27.8M | — |
8季度趋势，按日历期对齐
经营现金流ADMAGDYN
| Q1 26 | — | — | ||
| Q4 25 | $35.6M | $9.9M | ||
| Q3 25 | $13.3M | $7.0M | ||
| Q2 25 | $21.1M | $14.4M | ||
| Q1 25 | $-19.7M | $9.4M | ||
| Q4 24 | $50.2M | $7.1M | ||
| Q3 24 | $25.0M | $9.2M | ||
| Q2 24 | $45.6M | $10.7M |
自由现金流ADMAGDYN
| Q1 26 | — | — | ||
| Q4 25 | $34.6M | $6.1M | ||
| Q3 25 | $-1.1M | $2.9M | ||
| Q2 25 | $18.7M | $10.2M | ||
| Q1 25 | $-24.4M | $6.0M | ||
| Q4 24 | $47.5M | $4.4M | ||
| Q3 24 | $24.0M | $5.9M | ||
| Q2 24 | $43.6M | $8.0M |
自由现金流率ADMAGDYN
| Q1 26 | — | — | ||
| Q4 25 | 24.8% | 5.7% | ||
| Q3 25 | -0.8% | 2.8% | ||
| Q2 25 | 15.3% | 10.1% | ||
| Q1 25 | -21.2% | 6.0% | ||
| Q4 24 | 40.4% | 4.4% | ||
| Q3 24 | 20.0% | 6.8% | ||
| Q2 24 | 40.7% | 9.7% |
资本支出强度ADMAGDYN
| Q1 26 | — | — | ||
| Q4 25 | 0.8% | 3.6% | ||
| Q3 25 | 10.7% | 3.9% | ||
| Q2 25 | 2.0% | 4.1% | ||
| Q1 25 | 4.1% | 3.3% | ||
| Q4 24 | 2.3% | 2.6% | ||
| Q3 24 | 0.9% | 3.7% | ||
| Q2 24 | 1.9% | 3.2% |
现金转化率ADMAGDYN
| Q1 26 | — | — | ||
| Q4 25 | 0.72× | 32.34× | ||
| Q3 25 | 0.36× | 5.92× | ||
| Q2 25 | 0.62× | 2.73× | ||
| Q1 25 | -0.73× | 3.21× | ||
| Q4 24 | 0.45× | 1.56× | ||
| Q3 24 | 0.70× | 2.15× | ||
| Q2 24 | 1.42× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
GDYN
暂无分部数据
